An observational study in Phyllodes Breast Tumor, Artificial Intelligence and Multiomics, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 4 sites in China. Open to female participants. Per ClinicalTrials.gov, last updated 2024-02-29.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border, stromal cellularity, stromal atypia, mitotic activity and stromal overgrowth. Malignant PTs account for 18%-25%, with high local recurrence (up to 65%) and distant metastasis rates (16%-25%). Benign PT could progress to malignancy after multiple recurrences. Therefore, Early, accurate diagnosis and identification of therapeutic targets are crucial for improving outcomes and survival rates.
In recent years, there has been growing interest in the application of artificial intelligence (AI) in medical diagnostics. AI can integrate clinical information, histopathological images, and multi-omics data to assist in pathological and clinical diagnosis, prognosis prediction, and molecular profiling.AI has shown promising results in various areas, including the diagnosis of different cancers such as colorectal cancer, breast cancer, and prostate cancer. However, PT differs from breast cancer in diagnosis and treatment approach. Therefore, establishing an AI-based system for the precise diagnosis and prognosis assessment of PT is crucial for personalized medicine.
The research team, led by Dr. Nie Yan, is one of the few in Guangdong Province and even nationally, specializing in PT research. Their team has been conducting research on the malignant progression, metastasis mechanisms, and molecular markers for PT. The team has identified key mechanisms, such as fibroblast-to-myofibroblast differentiation, and the role of tumor-associated macrophages in promoting this differentiation. They have also identified molecular markers, including miR-21, α-SMA, CCL18, and CCL5, which are more accurate in predicting tumor recurrence risk compared to traditional histopathological grading.
The project has collected high-quality data from nearly a thousand breast PT patients, including imaging, histopathology, and survival data, and has performed transcriptome gene sequencing on tissue samples. They aim to build a comprehensive multi-omics database for breast PT and create an AI-based model for early diagnosis and prognosis prediction. This research has the potential to improve the diagnosis and treatment of breast PT, address the disparities in breast PT care across different regions in China, and contribute to the development of new therapeutic targets.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients are all those who attended Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients diagnosed with phyllodes tumor of breast
Diagnostic Test: imaging
Patient medical imaging materials including ultrasound, mammography, CT, MRI
Sensitivity
The probability of a positive test result, conditional on it being truly positive.
Time frame: Five years
False-negative Rate
Determine the odds of testing negative in a positive population.
Time frame: Five years
Specificity
The probability of a negative test result conditional on a true negative.
Time frame: Five years
False-positive Rate
Determine the odds of testing positive in a negative population.
Time frame: Five years
Receiver Operating Characteristic Curve
The ROC curve is a curve based on a series of different dichotomous classifications (cut-off values or decision thresholds), with the rate of true positives (sensitivity) as the vertical coordinate and the rate of false positives (1-specificity) as the horizontal coordinate.
Time frame: Five years
Area under roc Curve
AUC is defined as the area under the ROC curve enclosed with the axes, and the closer the AUC is to 1.0, the more authentic the assay is.
Time frame: Five years
Plan to share: No — no plan to make individual participant data available to other researchers.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Phyllodes Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →